Press Releases | Centessa Pharmaceuticals

Year

February 6, 2023

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present additional data from the

February 2, 2023

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference

BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a

January 26, 2023

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody being developed for solid tumors BOSTON and LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 13 of 13